US 12,435,065 B2
Crystalline forms of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide
Joachim Gebhardt, Ludwigshafen (DE); Martin Viertelhaus, Ludwigshafen (DE); Tiziana Chiodo, Ludwigshafen (DE); Michael Rack, Ludwigshafen (DE); Eric George Klauber, Huntsville, AL (US); Wen Xu, Research Triange Park, NC (US); Roland Goetz, Ludwigshafen (DE); Florian Vogt, Ludwigshafen (DE); Birgit Gockel, Ludwigshafen (DE); and Sebastian Soergel, Limburgerhof (DE)
Assigned to BASF SE, Ludwigshafen (DE)
Appl. No. 17/311,403
Filed by BASF SE, Ludwigshafen (DE)
PCT Filed Jan. 10, 2020, PCT No. PCT/EP2020/050493
§ 371(c)(1), (2) Date Jun. 7, 2021,
PCT Pub. No. WO2020/144308, PCT Pub. Date Jul. 16, 2020.
Claims priority of application No. 19151447 (EP), filed on Jan. 11, 2019.
Prior Publication US 2022/0024898 A1, Jan. 27, 2022
Int. Cl. C07D 403/12 (2006.01); A01N 43/58 (2006.01); A01P 7/04 (2006.01)
CPC C07D 403/12 (2013.01) [A01N 43/58 (2013.01); A01P 7/04 (2021.08); C07B 2200/13 (2013.01)] 13 Claims
 
1. A crystalline form B of 1-(1,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide, which in an X-ray powder diffraction diagram at 25° C. and Cu-Kα radiation displays the 3 following reflections, quoted as 2θ values: 20.69±0.10°, 24.15±0.10° and 30.52±0.10° and further displays at least two of the following reflections, quoted as 2θ values: 10.07±0.10°, 15.31±0.10°, 15.97±0.10° 16.50±0.10°, 19.29±0.10°, 20.22±0.10°, 20.96±0.10° and 26.09±0.10°.